Curis (NASDAQ:CRIS) reported a net income of $19.4 million for Q4 2025, driven solely by a $27.2 million one-time non-cash gain from selling its final Erivedge royalty stake to Oberland. The company explicitly confirmed that all recurring revenue ceased in November 2025, marking a complete operational pivot. Funding now depends on a $40.4 million PIPE financing (with $20.2 million milestone-linked) to sustain operations into 2027. Management is prioritizing two clinical programs: the registrational TakeAim Lymphoma trial in primary CNS lymphoma (PCNSL) and a proof-of-concept study in chronic lymphocytic leukemia (CLL). Initial CLL data is targeted for the ASH 2026 conference, while PCNSL enrollment is on track for a potential 2027 filing. The stock’s fate hinges on these trials’ success and the need for further capital.
The One-Time Windfall and the End of Recurring Revenue
Curis’s Q4 2025 earnings report opens with a number that demands immediate context: a $19.4 million net income, or $1.23 per share. This figure is not the result of organic business growth but a $27.2 million non-cash gain from the final sale of Erivedge royalties to Oberland. The transaction was the last step in a multi-year process to offload legacy assets, and management was unequivocal about the new reality.
Chief Executive Officer James E. Dentzer stated during the earnings call, “We sold what was remaining to Oberland to clean it all up. We are now completely independent of the Erivedge stream.” Chief Financial Officer Diantha Duvall reinforced this, confirming, “Revenue effectively ended in November 2025.” The small residual royalty stream (approximately 15% of the original) was sold along with the rest, meaning no future cash flow from the company’s former cornerstone asset will materialize. For investors, this is a critical demarcation: Curis is now a pure clinical-stage biopharmaceutical with no product revenue.
Cash Runway: A Bridge to 2027, But Not Beyond
With revenue gone, the balance sheet becomes the sole lifeline. As of December 31, 2025, Curis held cash and equivalents that, when combined with $20.2 million in gross proceeds from a January 2026 Private Investment in Public Equity (PIPE) financing, are projected to fund operations into 2027. A further $20.2 million is potentially available upon the public announcement of dosing the fifth patient in the TakeAim CLL study—a milestone expected later in 2026.
This financing structure creates a clear, near-term catalyst but also imposes a hard timeline. The company’s entire operational plan is built around a 12- to 18-month window from full enrollment in its flagship registrational trial. Management’s own words frame the urgency: the cash bridge is solid, yet it does not extend beyond 2027 without additional financing events. Investors must now evaluate whether the clinical data pipeline can justify a future capital raise or, in a best-case scenario, attract a partnership or acquisition before the cash runway expires.
Clinical Strategy: All-In on NHL, With CLL as the Juggernaut
Curis’s resource allocation is transparent and focused. The company has explicitly prioritized non-Hodgkin lymphoma (NHL) ahead of acute myeloid leukemia (AML). Within NHL, two tracks are active:
- TakeAim Lymphoma (PCNSL): This is a single-arm, registrational study evaluating emavusertib in combination with ibrutinib for primary CNS lymphoma, a rare and aggressive subtype. The endpoint is overall response rate (ORR). Management confirmed enrollment is “on track,” with full completion anticipated in the next 12 to 18 months. A successful trial could support accelerated FDA and EMA submissions, potentially placing a Curis therapy on the market by 2027.
- TakeAim CLL: This is a proof-of-concept study in chronic lymphocytic leukemia, the largest NHL subtype by patient population. Clinical sites have been activated in the U.S. and Europe. Initial data is targeted for presentation at the American Society of Hematology (ASH) Annual Meeting in December 2026. The dosing of the fifth CLL patient triggers the final $20.2 million PIPE tranche, tightly linking a financial milestone to clinical execution.
Why this dual focus? Dentzer explained the logic: “We are definitely prioritizing NHL ahead of AML.” He noted that the bulk of current spend is on PCNSL because it is a direct path to registration, while CLL, though still early, represents a much larger commercial opportunity. “In these early days CLL is much smaller, but I imagine that over time that will get larger,” he said. The strategy is to secure a regulatory win in a rare cancer (PCNSL) to establish a proof-of-concept for emavusertib’s mechanism, while simultaneously de-risking the commercial potential by testing in the prevalent CLL indication.
AML Triplet Data: Encouraging but a Secondary Priority
Results from the AML triplet study (emavusertib + azacitidine + venetoclax) presented at ASH 2024 showed five of eight evaluable patients achieved measurable residual disease (MRD) conversion. This is a positive signal, as MRD negativity is associated with deeper and more durable remissions. Chief Medical Officer Ahmed M. Hamdy expressed optimism about the dual-pathway inhibition strategy (targeting both the B-cell receptor and TLR/NF-kappa B pathways) that underlies emavusertib’s mechanism.
However, AML is not the current focus. Dentzer was clear: “As we are able to raise more cash, and we can get more work started, I think that is when we start to look at AML. Right now, the bulk of the work in AML is more analyzing what steps we want to take.” This is a crucial point for investors: the most advanced data outside the NHL focus is still early-stage and not currently consuming significant resources. The path forward in AML is contingent on future capital raises, making it a longer-term and more uncertain bet.
The Investment Thesis: Clinical Catalysts vs. Capital Needs
The market’s valuation of Curis now rests on a simple equation: the probability of success in PCNSL and CLL versus the probability of needing to raise more capital before achieving that success. The near-term catalysts are:
- PCNSL trial enrollment progress and eventual full enrollment.
- ASH 2026 (December) presentation of initial CLL proof-of-concept data.
- Announcement of dosing the fifth CLL patient, unlocking the final $20.2 million PIPE tranche.
The risks are equally clear. The company has no revenue and will burn cash. If PCNSL enrollment is slower than expected or CLL data is underwhelming, the stock could face severe downward pressure as the need for a dilutive financing looms. Conversely, strong data in either indication could trigger a significant re-rating, potentially attracting a partnership that would provide non-dilutive funding and a path to commercial validation.
Investors should also note the competitive landscape. In CLL, the standard of care is Bruton’s tyrosine kinase inhibitors (BTKis). Curis’s hypothesis is that adding emavusertib to a BTKi can deepen responses to complete remission and potentially enable time-limited treatment. This is a high-risk, high-reward bet against the dominant class of therapies. The company’s prior data in other NHL subtypes (like PCNSL) showing complete remissions provides some validation of the mechanism, but CLL is a much larger and more competitive battlefield.
Bottom Line: A Binary Outcome Shaped by 2026 Data
Curis has undergone a radical transformation. The one-time gain from the Erivedge sale provides a fleeting snapshot of profitability but masks a company at a decisive inflection point. The elimination of all recurring revenue forces investors to evaluate Curis purely on the clinical potential of its pipeline and the management team’s ability to execute against a tightly constrained cash runway.
The next 12 to 18 months are defining. Success in the PCNSL registrational trial could lead to a filing and a potential approval by 2027. Positive CLL proof-of-concept data at ASH 2026 would validate the broader commercial thesis and likely unlock the final PIPE tranche. Failure to meet these milestones, or delays that push the cash runway perilously close to expiration, would almost certainly force a dilutive capital raise at a steep discount, significantly diluting current shareholders.
For investors with a high risk tolerance, Curis represents a classic clinical-stage binary play: the upside is a multi-fold return if the trials succeed and the company either partners or commercializes independently; the downside is substantial loss of capital if execution falters or additional funding cannot be secured on reasonable terms. Monitor enrollment updates, the precise content of the ASH 2026 abstract, and any announcements regarding the fifth CLL patient dosing. These are the levers that will determine the stock’s trajectory in 2026.
onlytrustedinfo.com is committed to delivering the fastest, most authoritative analysis on breaking financial news. Our team of senior finance editors cuts through the noise to provide investors with the context and insight needed to make informed decisions. For more in-depth coverage of biopharma catalysts, clinical trial readouts, and strategic corporate pivots, read more articles on onlytrustedinfo.com.
